How to Reconstitute BPC-157: Syringe Selection and Needle Gauge Guide

What Syringe Should You Use for BPC-157?

A 0.3 mL U-100 insulin syringe with a fixed 31-gauge, 5/16-inch needle is the standard choice for subcutaneous BPC-157 administration. The fixed-needle design eliminates the dead-space volume seen in detachable-needle syringes, which matters when doses are measured in single-digit units on the barrel. For intramuscular (IM) delivery, a 1 mL syringe with a detachable 25- or 27-gauge, 1-inch needle gives the depth needed without excessive trauma.

Why Dead-Space Volume Matters for Peptide Dosing

Dead space is the fluid that remains trapped in a syringe's hub or needle after the plunger bottoms out. Standard detachable-needle syringes can retain 50 to 150 mcL of fluid per draw. At a working concentration of 2,500 mcg/mL, 100 mcL of dead space equals 250 mcg of lost peptide per injection. Over a 4-week protocol, that loss compounds quickly.

Fixed-needle insulin syringes eliminate most of this waste. The BD Ultra-Fine II 0.3 mL syringe, for example, is listed by the manufacturer as having near-zero dead space at the needle hub. USP General Chapter <1> on injections describes the importance of low-dead-volume devices when administering high-potency, low-volume biological preparations [1].

Gauge Selection by Route

| Route | Gauge | Needle Length | Notes | |---|---|---|---| | Subcutaneous (SQ) | 27 to 31 G | 5/16 to 1/2 inch | Finer gauge means less pain; 31 G is preferred | | Intramuscular (IM) | 25 to 27 G | 1 to 1.5 inch | Deltoid: 1 inch; Glute/vastus: 1 to 1.5 inch | | Reconstitution only | 18 to 21 G | 1 inch | Use a separate, larger-bore needle to draw diluent, then swap |

Using a 31-gauge needle for reconstitution itself is possible but slow. A practical workflow uses an 18-gauge needle to pull bacteriostatic water into a transfer syringe, inject it gently into the peptide vial, then discard that needle and attach a fresh 31-gauge for the actual injection.

Syringe Volume and Graduation Precision

A 0.3 mL U-100 syringe has 30 graduation marks, each representing 1 unit (10 mcL). At 2,500 mcg/mL that equals 25 mcg per graduation. A 1 mL U-100 syringe has 100 graduations of the same size but is physically harder to read at low volumes. For doses of 250 to 500 mcg, the 0.3 mL barrel is almost always the right call.

How to Reconstitute BPC-157 Step by Step

Reconstitution is a sterile compounding procedure. The steps below align with USP General Chapter <797> low-risk handling requirements for non-hazardous sterile preparations [2].

What You Need Before You Start

• BPC-157 lyophilized vial (typically 5 mg)
• Bacteriostatic water for injection, USP (30 mL multi-dose vial)
• Two syringes: one 3 mL or 5 mL syringe with 18-gauge needle (for pulling diluent), one 1 mL insulin syringe for injecting into the peptide vial
• Alcohol swabs (70% isopropyl)
• Clean, flat surface (not carpeted)
• Nitrile gloves

The Reconstitution Procedure

1. Wash hands with soap for at least 20 seconds.
2. Put on nitrile gloves.
3. Wipe both vial tops (bacteriostatic water and peptide vial) with a fresh alcohol swab. Allow 30 seconds to dry fully. Do not fan or blow on the surface.
4. Draw the desired volume of bacteriostatic water into the transfer syringe. For a 5 mg vial using the standard 2 mL protocol, draw 2.0 mL.
5. Insert the needle into the peptide vial at a 45-degree angle. Inject the water slowly down the inner glass wall, not directly onto the lyophilized cake. Forcing liquid onto the cake can denature fragile peptide bonds.
6. Do not shake the vial. Gently swirl or roll between your palms until the powder dissolves completely. BPC-157 typically clears within 30 to 60 seconds.
7. Inspect the solution. It should be clear and colorless, with no visible particles. Discard if cloudy or particulate is seen.
8. Label the vial with the date of reconstitution, concentration, and your initials.
9. Refrigerate immediately at 2 to 8 °C.

The slow-wall-injection technique is consistent with guidance from the American Society of Health-System Pharmacists (ASHP) on protein and peptide reconstitution, which specifically cautions against direct stream injection onto lyophilized biologicals [3].

Why Bacteriostatic Water and Not Sterile Water

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative. That preservative prevents microbial growth across the 28-day default beyond-use date (BUD) assigned to low-risk compounded sterile preparations under USP <797> [2]. Plain sterile water for injection (SWFI) carries no preservative and must be used as a single-dose product. Because most BPC-157 protocols span multiple weeks with daily draws from the same vial, bacteriostatic water is the correct diluent choice for multi-dose use.

Benzyl alcohol at the concentration found in bacteriostatic water (9 mg/mL) is FDA-recognized as generally safe in adults. The FDA issued guidance limiting benzyl alcohol-preserved products in neonates due to gasping syndrome, but that restriction does not apply to adult use [4].

BPC-157 Dosing Calculator: Concentration Math

Getting the concentration math right is the single most error-prone step for new users. The formula is straightforward once you fix one variable.

Standard Concentration: 2,500 mcg per mL

Add 2 mL of bacteriostatic water to a 5 mg (5,000 mcg) vial:

5,000 mcg divided by 2 mL = 2,500 mcg per mL

On a U-100 insulin syringe, each unit = 0.01 mL = 10 mcL. So:

• 250 mcg dose = 0.10 mL = 10 units
• 500 mcg dose = 0.20 mL = 20 units
• 750 mcg dose = 0.30 mL = 30 units

Alternative Concentration: 1,000 mcg per mL

Some clinicians prefer a more dilute solution to improve volume precision at lower doses. Adding 5 mL to the same 5 mg vial yields 1,000 mcg/mL:

• 250 mcg dose = 0.25 mL = 25 units
• 500 mcg dose = 0.50 mL = 50 units

This dilution makes 250 mcg doses easier to measure accurately on the barrel but requires a larger injection volume, which may cause more tissue discomfort at the SQ injection site.

Concentration Cross-Check Table

| Bacteriostatic Water Added | Concentration | 250 mcg Dose Volume | 500 mcg Dose Volume | |---|---|---|---| | 1 mL | 5,000 mcg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) | | 2 mL | 2,500 mcg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) | | 5 mL | 1,000 mcg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) | | 10 mL | 500 mcg/mL | 0.50 mL (50 units) | 1.00 mL (100 units) |

The 1 mL reconstitution is not recommended for routine use. At 5,000 mcg/mL, a single graduation error (1 unit = 50 mcg) represents a 20% dosing error on a 250 mcg target. That margin is clinically meaningful.

Injection Technique for Subcutaneous BPC-157

Subcutaneous injection delivers BPC-157 into the adipose layer just below the skin, typically in the abdomen, lateral thigh, or flank. The tissue is loose and well-vascularized enough for adequate absorption without the discomfort of IM injection.

Site Selection and Rotation

Rotate injection sites with every dose. Repeated injections into the same spot cause lipohypertrophy, a localized thickening of the subcutaneous fat that reduces absorption reliability. The abdomen offers the largest surface area for rotation. Stay at least 2 inches away from the navel. The lateral thigh is the secondary preference.

SQ Injection Steps

1. Wipe the chosen skin site with an alcohol swab. Wait 30 seconds.
2. Pinch a fold of skin between thumb and forefinger to lift the subcutaneous layer away from underlying muscle.
3. Insert the needle at 45 to 90 degrees depending on skin thickness. Thinner individuals should use 45 degrees; those with more subcutaneous fat can use 90 degrees.
4. Release the skin fold. Inject slowly, over about 5 seconds for a 0.1 to 0.2 mL dose.
5. Withdraw the needle smoothly. Apply gentle pressure with a clean cotton ball. Do not rub.
6. Dispose of the needle immediately in a sharps container. Never recap with two hands.

The CDC's injection safety guidelines specify that needles must never be recapped using two hands and must be placed in an FDA-cleared sharps container immediately after use [5].

IM Injection: When and How

IM delivery may be appropriate when a clinician wants faster peak plasma exposure or when SQ injection is not tolerated. For IM BPC-157, the deltoid (1-inch needle, 25 to 27 gauge) or vastus lateralis (1 to 1.5-inch needle, 25 gauge) are typical sites. Aspiration before injection remains debated; the CDC no longer recommends routine aspiration for vaccines, but many compounding physicians retain the step for non-vaccine peptides to confirm non-intravascular placement [5].

Stability, Storage, and Beyond-Use Dating

Reconstituted BPC-157 stability data from published peptide chemistry research indicates that BPC-157 in aqueous solution at physiologic pH remains chemically stable for at least several weeks under refrigeration, though precise peer-reviewed stability profiling is limited compared to approved biologicals [6].

Storage Conditions

• Unreconstituted lyophilized powder: Store at -20 °C for long-term (up to 24 months in some manufacturer specifications). Short-term storage at 4 °C is acceptable for up to 3 months.
• Reconstituted vial: Refrigerate at 2 to 8 °C. Use within 28 days per USP <797> low-risk BUD for preserved multi-dose preparations [2].
• Do not freeze the reconstituted vial. Ice crystal formation can physically disrupt peptide secondary structure.
• Protect from light. UV exposure accelerates oxidative degradation of the pentadecapeptide backbone [6].

Signs of Degradation

Discard the vial without hesitation if you observe:

• Cloudiness or haze in what should be a clear solution
• Visible particles or flocculation
• Yellow or amber discoloration
• Any off odor when the stopper is punctured

USP <797> requires that all compounded sterile preparations be inspected visually before each use and discarded if there is any doubt about integrity [2].

BPC-157 Pharmacology Relevant to Reconstitution Choices

Understanding why BPC-157 behaves the way it does in solution helps explain the technical recommendations above.

Peptide Structure and Solubility

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a gastric protein. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) confers moderate water solubility and resistance to enzymatic degradation compared to shorter peptides. Animal studies published in peer-reviewed journals have shown that BPC-157 resists degradation by gastric juice in a rat model, though this property is distinct from its stability in buffered aqueous solution at refrigerated temperatures [7].

Absorption After SQ vs. IM Injection

No published human pharmacokinetic trial has directly compared SQ versus IM bioavailability for BPC-157 in humans as of mid-2025, which is an honest gap in the literature. Animal data suggest that both routes achieve systemic distribution, with IM showing a modestly faster time to peak concentration. The practical implication: SQ is preferred for convenience and lower tissue trauma, IM is an option when a clinician specifically wants faster onset in an acute injury context.

pH Sensitivity

Bacteriostatic water for injection has a pH of approximately 4.5 to 7.0 depending on manufacturer lot. BPC-157 is relatively stable across this pH range. Avoid reconstituting in normal saline (0.9% NaCl), which lacks a preservative and introduces chloride ions that can accelerate peptide bond hydrolysis over a multi-week storage period. The ASHP's guidance on peptide stability in solution recommends matching diluent pH to the peptide's isoelectric point where possible and defaulting to bacteriostatic water for multi-dose peptide preparations [3].

Common Reconstitution Errors and How to Avoid Them

Error 1: Shaking the Vial

Vigorous shaking introduces air bubbles and mechanical shear forces that can cause peptide aggregation. Swirl gently. This is consistent with protein handling guidance published in the Journal of Pharmaceutical Sciences showing that mechanical agitation of protein solutions increases aggregation rates measurably [8].

Error 2: Injecting Water Directly onto the Lyophilized Cake

Direct stream injection causes localized heat from impact and disrupts the porous lyophilized matrix unevenly. Angle the needle so the liquid runs down the inner vial wall and wicks into the cake from below. Dissolution is slower this way but more complete.

Error 3: Using the Wrong Syringe Scale

A U-40 insulin syringe (used for veterinary insulin) has a different unit scale than a U-100 syringe. If you draw BPC-157 solution reconstituted for a U-100 scale using a U-40 syringe, you will draw 2.5 times the intended dose. U-100 syringes are the standard for human use in the United States. Confirm "U-100" is printed on the barrel before drawing.

Error 4: Storing the Reconstituted Vial at Room Temperature

Room temperature storage (20 to 25 °C) significantly shortens peptide stability in aqueous solution. A study examining synthetic peptide degradation kinetics found that storage at 25 °C increased degradation rates by a factor of 3 to 5 compared with 4 °C refrigeration for structurally similar pentapeptides [9]. Move the vial to the refrigerator within 5 minutes of reconstitution.

Error 5: Reusing Needles

A 31-gauge needle tip deforms measurably after a single use. Reusing it increases injection pain, increases risk of barb-related tissue trauma, and compromises sterility. Each injection requires a fresh needle. The CDC's injection safety program specifies one needle, one syringe, one time as a non-negotiable principle [5].

Regulatory and Safety Context

BPC-157 is not FDA-approved as a drug. It is not currently on the FDA's list of bulk drug substances that may be used in compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. In March 2022, the FDA added BPC-157 to its list of substances that present "significant safety concerns" for use in compounding, citing the absence of adequate clinical safety data in humans [10].

This regulatory status means:

• BPC-157 obtained from compounding pharmacies in the U.S. Exists in a complex legal gray area following the 2022 FDA action.
• Clinical oversight by a licensed physician is important from both a safety and legal standpoint.
• Quality varies between suppliers. Purity testing by a third-party ISO/IEC 17025-accredited laboratory should be expected from any reputable source.

The FDA's stated concern is not that BPC-157 is proven harmful, but that the human safety database is insufficient to conclude it is safe at compounded doses. That distinction matters when counseling patients about risk-benefit.